{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:33Z","timestamp":1786991073008,"version":"build-2736575974"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374332"],"award-info":[{"award-number":["82374332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZZYSM202311014"],"award-info":[{"award-number":["SZZYSM202311014"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.intimp.2025.114708","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T18:47:53Z","timestamp":1745952473000},"page":"114708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Natural bioactive compounds reprogram bile acid metabolism in MAFLD: Multi-target mechanisms and therapeutic implications"],"prefix":"10.1016","volume":"157","author":[{"given":"Dongjie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2025.114708_bb0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.114708_bb0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-med-042220-020407","article-title":"Fatty liver disease: diagnosis and stratification","volume":"73","author":"Saiman","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"11","key":"10.1016\/j.intimp.2025.114708_bb0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114708_bb0020","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0025","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"9","key":"10.1016\/j.intimp.2025.114708_bb0030","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s10620-024-08540-4","article-title":"Sex and race-ethnic disparities in metabolic dysfunction-associated steatotic liver disease: an analysis of 40,166 individuals","volume":"69","author":"Fu","year":"2024","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.114708_bb0035","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cam4.4551","article-title":"Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.intimp.2025.114708_bb0040","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.intimp.2025.114708_bb0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0055","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12916-024-03315-0","article-title":"Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis","volume":"22","author":"Cao","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2025.114708_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115333","article-title":"Penthorum chinense Pursh. Extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice","volume":"294","author":"Li","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes","volume":"78","author":"Pennisi","year":"2023","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.intimp.2025.114708_bb0075","doi-asserted-by":"crossref","unstructured":"X.D. Zhou, G. Targher, C.D. Byrne, V. Somers, S.U. Kim, C.A.A. Chahal, V.W. Wong, J. Cai, M.D. Shapiro, M. Eslam, P.G. Steg, K.C. Sung, A. Misra, J.J. Li, C. Brotons, Y. Huang, G.V. Papatheodoridis, A. Sun, Y. Yilmaz, W.K. Chan, H. Huang, N. M\u00e9ndez-S\u00e1nchez, S.A. Alqahtani, H. Cortez-Pinto, G.Y.H. Lip, R.J. de Knegt, P. Ocama, M. Romero-Gomez, M. Fudim, G. Sebastiani, J.W. Son, J.D. Ryan, I. Ikonomidis, S. Treeprasertsuk, D. Pastori, M. Lupsor-Platon, H. Tilg, H. Ghazinyan, J. Boursier, M. Hamaguchi, M.H. Nguyen, J.G. Fan, G.B. Goh, M. Al Mahtab, S. Hamid, N. Perera, J. George, M.H. Zheng, An international multidisciplinary consensus statement on MAFLD and the risk of CVD, Hepatol. Int. 17(4) (2023) 773\u2013791.","DOI":"10.1007\/s12072-023-10543-8"},{"issue":"5","key":"10.1016\/j.intimp.2025.114708_bb0080","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2021.02.002","article-title":"MAFLD: now is the time to capitalize on the momentum","volume":"74","author":"Eslam","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2025.114708_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2022.101210","article-title":"Bile acids and their receptors in regulation of gut health and diseases","volume":"89","author":"Lin","year":"2023","journal-title":"Prog. Lipid Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.114708_bb0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-024-00914-3","article-title":"The changing metabolic landscape of bile acids \u2013 keys to metabolism and immune regulation","volume":"21","author":"Mohanty","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114708_bb0100","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ecl.2023.01.004","article-title":"Metabolic-associated fatty liver disease and the gut microbiota","volume":"52","author":"Barber","year":"2023","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"17","key":"10.1016\/j.intimp.2025.114708_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/nu15173722","article-title":"Polysaccharides: the potential prebiotics for metabolic associated fatty liver disease (MAFLD)","volume":"15","author":"Guo","year":"2023","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.intimp.2025.114708_bb0115","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0120","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.intimp.2025.114708_bb0125","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0130","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.intimp.2025.114708_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112806","article-title":"Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease","volume":"10","author":"Xue","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2025.114708_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114987","article-title":"Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT\/NAD(+)\/SIRT1 axis","volume":"164","author":"Yang","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"13","key":"10.1016\/j.intimp.2025.114708_bb0145","article-title":"Ginsenoside Rh4 improves hepatic lipid metabolism and inflammation in a model of NAFLD by targeting the gut liver axis and modulating the FXR signaling pathway","volume":"12","author":"Yang","year":"2023","journal-title":"Foods (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2025.114708_bb0150","doi-asserted-by":"crossref","first-page":"1072376","DOI":"10.3389\/fimmu.2022.1072376","article-title":"Gut microbiota: the key to the treatment of metabolic syndrome in traditional Chinese medicine - a case study of diabetes and nonalcoholic fatty liver disease","volume":"13","author":"Bao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.114708_bb0155","article-title":"Exploring the underlying mechanisms of obesity and diabetes and the potential of traditional Chinese medicine: an overview of the literature","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1142\/S0192415X21500130","article-title":"Intestinal Flora: a pivotal role in investigation of traditional Chinese medicine","volume":"49","author":"Li","year":"2021","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.intimp.2025.114708_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110857","article-title":"Therapeutic mechanisms of traditional Chinese medicine to improve metabolic diseases via the gut microbiota","volume":"133","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of bile acids in metabolic control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.apsb.2015.01.001","article-title":"Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids","volume":"5","author":"Ferrebee","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2025.114708_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.114708_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.intimp.2025.114708_bb0190","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2025.114708_bb0195","doi-asserted-by":"crossref","unstructured":"A. Di Ciaula, G. Garruti, R. Lunardi Baccetto, E. Molina-Molina, L. Bonfrate, D.Q. Wang, P. Portincasa, Bile Acid Physiology, Annals of hepatology 16(Suppl. 1: s3\u2013105.) (2017) s4-s14.","DOI":"10.5604\/01.3001.0010.5493"},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041780","article-title":"Physiology and physical chemistry of bile acids","volume":"22","author":"di Gregorio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.114708_bb0205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13238-020-00804-9","article-title":"Targeting the alternative bile acid synthetic pathway for metabolic diseases","volume":"12","author":"Jia","year":"2021","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0215","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.chom.2022.02.004","article-title":"Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis","volume":"30","author":"Cai","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.intimp.2025.114708_bb0225","doi-asserted-by":"crossref","first-page":"E1225","DOI":"10.1210\/jc.2015-2467","article-title":"Early increases in bile acids post roux-en-Y gastric bypass are driven by insulin-sensitizing, secondary bile acids","volume":"100","author":"Albaugh","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0230","first-page":"E121","article-title":"Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption, American journal of physiology","volume":"313","author":"Bertaggia","year":"2017","journal-title":"Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0235","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2337\/db14-0716","article-title":"Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1","volume":"64","author":"Kaur","year":"2015","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.intimp.2025.114708_bb0240","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1194\/jlr.RA120000924","article-title":"Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition","volume":"61","author":"Kakiyama","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.intimp.2025.114708_bb0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsbmb.2019.01.011","article-title":"Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols","volume":"189","author":"Kakiyama","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114708_bb0250","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1096\/fj.201701084RR","article-title":"Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice","volume":"32","author":"Chevre","year":"2018","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100387","article-title":"Bile acids contribute to the development of non-alcoholic steatohepatitis in mice","volume":"4","author":"Gillard","year":"2022","journal-title":"JHEP Reports: Innov. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13679-019-00334-4","article-title":"Changes in bile acid metabolism, transport, and signaling as central drivers for metabolic improvements after bariatric surgery","volume":"8","author":"Browning","year":"2019","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.intimp.2025.114708_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100134","article-title":"Low production of 12\u03b1-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70(\u2212\/\u2212) mice by reducing fat absorption","volume":"62","author":"Li","year":"2021","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.intimp.2025.114708_bb0270","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200148RR","article-title":"Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis","volume":"36","author":"Miao","year":"2022","journal-title":"FASEB J."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2025.114708_bb0275","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s12072-024-10660-y","article-title":"MAFLD as part of systemic metabolic dysregulation","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol. Int."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0280","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.livres.2019.05.001","article-title":"The acidic pathway of bile acid synthesis: not just an alternative pathway(\u2606)","volume":"3","author":"Pandak","year":"2019","journal-title":"Liver Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0285","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11154-019-09512-0","article-title":"Dietary lipids, gut microbiota and lipid metabolism","volume":"20","author":"Schoeler","year":"2019","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0290","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bph.14095","article-title":"Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease","volume":"175","author":"Wang","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114708_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2021.108869","article-title":"Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet","volume":"100","author":"Chun","year":"2022","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.intimp.2025.114708_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2020.104437","article-title":"Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5\/Dmcr rat model","volume":"114","author":"Yamamoto","year":"2020","journal-title":"Exp. Mol. Pathol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0305","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/s41401-024-01303-x","article-title":"A new mechanism of thyroid hormone receptor \u03b2 agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2025.114708_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102766","article-title":"A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility","volume":"55","author":"Wei","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0315","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2221098","article-title":"Deletion of hepatic growth hormone receptor (GHR) alters the mouse gut microbiota by affecting bile acid metabolism","volume":"15","author":"Yu","year":"2023","journal-title":"Gut Microbes"},{"issue":"12","key":"10.1016\/j.intimp.2025.114708_bb0320","article-title":"12\u03b1-Hydroxylated bile acid induces hepatic steatosis with dysbiosis in rats","volume":"1865","author":"Lee","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"11","key":"10.1016\/j.intimp.2025.114708_bb0325","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.5551\/jat.39909","article-title":"Cholic acid enhances visceral adiposity, atherosclerosis and nonalcoholic fatty liver disease in microminipigs","volume":"24","author":"Yamada","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"issue":"11","key":"10.1016\/j.intimp.2025.114708_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152599","article-title":"Dietary fat, cholesterol, and cholic acid affect the histopathologic severity of nonalcoholic steatohepatitis in Sprague-Dawley rats","volume":"215","author":"Fukuda","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"12","key":"10.1016\/j.intimp.2025.114708_bb0335","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1007\/s00432-020-03374-9","article-title":"Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma","volume":"146","author":"Nguyen","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0340","article-title":"The Yin and Yang of bile acid action on tight junctions in a model colonic epithelium","volume":"5","author":"Sarathy","year":"2017","journal-title":"Phys. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.114708_bb0345","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2036.2011.04611.x","article-title":"Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission","volume":"33","author":"M\u00fcnch","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.114708_bb0350","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1096\/fj.201902687R","article-title":"Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis","volume":"34","author":"Gupta","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.114708_bb0355","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lfs.2016.04.037","article-title":"Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes","volume":"156","author":"Krattinger","year":"2016","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0360","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2174\/1566524022666220525152811","article-title":"Ursodeoxycholic acid (UDCA) reduces hepatocyte apoptosis by inhibiting Farnesoid X receptor (FXR) in hemorrhagic shock (HS)","volume":"23","author":"Wang","year":"2023","journal-title":"Curr. Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0365","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bbrc.2020.05.128","article-title":"Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK","volume":"529","author":"Wu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0370","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.20246","article-title":"Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways","volume":"39","author":"Schoemaker","year":"2004","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0375","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0380","first-page":"696","article-title":"Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials","volume":"29","author":"Zhang","year":"2020","journal-title":"Asia Pac. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0385","doi-asserted-by":"crossref","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","article-title":"Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon","volume":"312","author":"Ward","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.intimp.2025.114708_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.910493","article-title":"The effect of lithocholic acid on the gut-liver axis","volume":"13","author":"Sheng","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0395","article-title":"Plants of the spontaneous flora with beneficial action in the management of diabetes, hepatic disorders, and cardiovascular disease","volume":"10","author":"Ignat","year":"2021","journal-title":"Plants (Basel, Switzerland)"},{"issue":"21","key":"10.1016\/j.intimp.2025.114708_bb0400","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1021\/acs.jmedchem.0c01065","article-title":"Discovery and optimization of non-bile acid FXR agonists as preclinical candidates for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0405","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1142\/S0192415X24500137","article-title":"Natural products in the modulation of Farnesoid X receptor against nonalcoholic fatty liver disease","volume":"52","author":"Wang","year":"2024","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.intimp.2025.114708_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107867","article-title":"The pathophysiological function of non-gastrointestinal farnesoid X receptor","volume":"226","author":"Yan","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2025.114708_bb0415","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/ptr.6486","article-title":"Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db\/db mice","volume":"33","author":"Yang","year":"2019","journal-title":"Phytother. Res."},{"issue":"8","key":"10.1016\/j.intimp.2025.114708_bb0420","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3748\/wjg.v27.i8.677","article-title":"G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment","volume":"27","author":"Yang","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2025.114708_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113577","article-title":"A new perspective on NAFLD: focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR)","volume":"154","author":"Zhou","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114708_bb0430","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2147\/DMSO.S304817","article-title":"Astragaloside IV alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease","volume":"14","author":"Liang","year":"2021","journal-title":"Diab. Metab. Syndr. Obesity: Targets Ther."},{"key":"10.1016\/j.intimp.2025.114708_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154444","article-title":"Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling","volume":"107","author":"Zhai","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.114708_bb0440","doi-asserted-by":"crossref","first-page":"9651371","DOI":"10.1155\/2017\/9651371","article-title":"Salidroside modulates insulin signaling in a rat model of nonalcoholic steatohepatitis","volume":"2017","author":"Li","year":"2017","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.intimp.2025.114708_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109915","article-title":"Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis","volume":"124","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114708_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106621","article-title":"Diosgenin alleviates nonalcoholic steatohepatitis through affecting liver-gut circulation","volume":"187","author":"Yan","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.intimp.2025.114708_bb0455","article-title":"The synbiotic combination of Akkermansia muciniphila and quercetin ameliorates early obesity and NAFLD through gut microbiota reshaping and bile acid metabolism modulation","volume":"10","author":"Ju\u00e1rez-Fern\u00e1ndez","year":"2021","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2025.114708_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.946360","article-title":"Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114708_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.643857","article-title":"Xanthohumol ameliorates diet-induced liver dysfunction via Farnesoid X receptor-dependent and independent signaling","volume":"12","author":"Paraiso","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0470","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/C9FO00263D","article-title":"A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice","volume":"10","author":"Huang","year":"2019","journal-title":"Food Funct."},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0475","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1159\/000493297","article-title":"Ganoderma Lucidum polysaccharide peptide alleviates Hepatoteatosis via modulating bile acid metabolism dependent on FXR-SHP\/FGF","volume":"49","author":"Zhong","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.intimp.2025.114708_bb0480","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bbrc.2022.02.033","article-title":"Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice","volume":"600","author":"Wang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2025.114708_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1218901","article-title":"Burden of liver cancer due to hepatitis C from 1990 to 2019 at the global, regional, and national levels","volume":"13","author":"Wei","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.114708_bb0490","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.tjnut.2023.05.026","article-title":"Stigmasterol protects against steatohepatitis induced by high-fat and high-cholesterol diet in mice by enhancing the alternative bile acid synthesis pathway","volume":"153","author":"Xin","year":"2023","journal-title":"J. Nutr."},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0495","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbalip.2018.08.004","article-title":"Intake of stigmasterol and \u03b2-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet","volume":"1863","author":"Feng","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.intimp.2025.114708_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750826","article-title":"Berberine alleviates non-alcoholic steatohepatitis through modulating gut microbiota mediated intestinal FXR activation","volume":"12","author":"Shu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020210","article-title":"Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.intimp.2025.114708_bb0510","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41430-018-0386-5","article-title":"A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Chashmniam","year":"2019","journal-title":"Eur. J. Clin. Nutr."},{"issue":"38","key":"10.1016\/j.intimp.2025.114708_bb0515","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1021\/acs.jafc.2c04817","article-title":"Nuciferine protects against high-fat diet-induced hepatic steatosis via modulation of gut microbiota and bile acid metabolism in rats","volume":"70","author":"Sun","year":"2022","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0520","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0525","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmed.2021.10.005","article-title":"Linking liver metabolic and vascular disease via bile acid signaling","volume":"28","author":"Fiorucci","year":"2022","journal-title":"Trends Mol. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.114708_bb0530","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0535","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0540","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"Smirnova","year":"2022","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"11","key":"10.1016\/j.intimp.2025.114708_bb0545","first-page":"620","article-title":"Bile acid species shows potential for NAFLD","volume":"19","author":"Starling","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10215","key":"10.1016\/j.intimp.2025.114708_bb0550","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.intimp.2025.114708_bb0555","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH","volume":"44","author":"Alkhouri","year":"2024","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0560","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12876-018-0805-z","article-title":"Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial","volume":"18","author":"Friedrich","year":"2018","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114708_bb0565","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajcnut.2024.05.017","article-title":"Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial","volume":"120","author":"He","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"issue":"9972","key":"10.1016\/j.intimp.2025.114708_bb0570","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.intimp.2025.114708_bb0575","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2025.114708_bb0580","first-page":"S46","article-title":"Treatment of nonalcoholic steatohepatitis by obeticholic acid: current status","volume":"12","author":"Roy","year":"2022","journal-title":"Euroasian J. Hepato-Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2025.114708_bb0585","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2264850","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study","volume":"55","author":"Xu","year":"2023","journal-title":"Ann. Med."},{"key":"10.1016\/j.intimp.2025.114708_bb0590","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2018.04.005","article-title":"Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease","volume":"190","author":"Yu","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2025.114708_bb0595","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01979-23","article-title":"Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota","volume":"12","author":"Chen","year":"2024","journal-title":"Microbiol. Spectr."},{"issue":"18","key":"10.1016\/j.intimp.2025.114708_bb0600","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1093\/cvr\/cvad169","article-title":"The inhibition of inner mitochondrial fusion in hepatocytes reduces non-alcoholic fatty liver and improves metabolic profile during obesity by modulating bile acid conjugation","volume":"119","author":"Da Dalt","year":"2024","journal-title":"Cardiovasc. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:52:44Z","timestamp":1762552364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925006988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":120,"alternative-id":["S1567576925006988"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114708","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural bioactive compounds reprogram bile acid metabolism in MAFLD: Multi-target mechanisms and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114708"}}